Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Griet Compernolle

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
The Journal of Biological Chemistry|February 28, 2004
Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug designBart De Taeye, Griet Compernolle, Paul J Declerck
Thrombosis and Haemostasis|July 24, 2003
Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibitionDominik Naessens, Ann Gils, Griet Compernolle, et al.
Thrombosis and Haemostasis|September 1, 2009
Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)Ann Gils, Lester M Meissenheimer, Griet Compernolle, et al.
Circulation Research|December 8, 2007
Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitorKarlien Buelens, Kerstin Hillmayer, Griet Compernolle, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 19, 2019
Anti-infliximab antibodies: How to compare old and new data?Maya Imbrechts, Thomas Van Stappen, Griet Compernolle, et al.
The Journal of Biological Chemistry|April 11, 2003
Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional propertiesBart De Taeye, Griet Compernolle, Maarten Dewilde, et al.
Inflammatory Bowel Diseases|August 19, 2015
An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel DiseasesThomas Van Stappen, Thomas Billiet, Niels Vande Casteele, et al.
Thrombosis Research|December 20, 2011
Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1Britt Van De Craen, Ilse Scroyen, Christine Vranckx, et al.
Journal of Structural Biology|March 17, 2010
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differencesMaarten Dewilde, Britt Van De Craen, Griet Compernolle, et al.
Journal of Crohn'S & Colitis|May 9, 2022
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative ColitisDahham Alsoud, Gert De Hertogh, Griet Compernolle, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
The Journal of Biological Chemistry|February 28, 2004
Site-directed targeting of plasminogen activator inhibitor-1 as an example for a novel approach in rational drug designBart De Taeye, Griet Compernolle, Paul J Declerck
Thrombosis and Haemostasis|July 24, 2003
Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibitionDominik Naessens, Ann Gils, Griet Compernolle, et al.
Thrombosis and Haemostasis|September 1, 2009
Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)Ann Gils, Lester M Meissenheimer, Griet Compernolle, et al.
Circulation Research|December 8, 2007
Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitorKarlien Buelens, Kerstin Hillmayer, Griet Compernolle, et al.
Journal of Pharmaceutical and Biomedical Analysis|September 19, 2019
Anti-infliximab antibodies: How to compare old and new data?Maya Imbrechts, Thomas Van Stappen, Griet Compernolle, et al.
The Journal of Biological Chemistry|April 11, 2003
Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional propertiesBart De Taeye, Griet Compernolle, Maarten Dewilde, et al.
Inflammatory Bowel Diseases|August 19, 2015
An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel DiseasesThomas Van Stappen, Thomas Billiet, Niels Vande Casteele, et al.
Thrombosis Research|December 20, 2011
Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1Britt Van De Craen, Ilse Scroyen, Christine Vranckx, et al.
Journal of Structural Biology|March 17, 2010
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differencesMaarten Dewilde, Britt Van De Craen, Griet Compernolle, et al.
Journal of Crohn'S & Colitis|May 9, 2022
Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative ColitisDahham Alsoud, Gert De Hertogh, Griet Compernolle, et al.
Pageof 3